A randomised comparison of ceftazidime and piperacillin, both in combination with flucloxacillin for treatment of febrile episodes in neutropenic children. Finnish Three-Centre Study.
111 febrile episodes in 98 neutropenic children were randomly treated with either ceftazidime (CAZ) 150 mg/kg/day or with piperacillin (PIP) 200 mg/kg/day, both combined with flucloxacillin (FLUC) 50 mg/kg/day. A total of 37/47 (79%) eligible episodes in the CAZ group and 41/53 (77%) in the PIP group were cured without needing to stop the initial therapy. The success without modification of the treatment in the verified septicaemias in the CAZ group was 8/18 (44%) and in the PIP group 5/18 (28%). Of the bacteriologically documented infections, 13/24 (54%) in the CAZ group and 11/24 (46%) in the PIP group were cured without modification of the therapy. Similarly, 17/31 (55%) of all the isolated bacteria in the CAZ group and 14/33 (42%) in the PIP group were eradicated with the initial therapy. Overall there were 13 deaths of which 4 in the CAZ group and 5 in the PIP group occurred during the infection. An increasing granulocyte count exceeding 0.25 x 10(9)/l at the end of the therapy was a good prognostic sign for the outcome of the infection. This study indicates that CAZ is as effective as PIP in the treatment of infections in neutropenic children.
Department of Paediatrics, University Hospital of Helsinki, Finland.
M
M
Perkkiö
L
L
Hovi
J
J
Rajantie
M
M
Lanning
T
T
Salmi
K
K
Williams
A
A
Mäkipernaa
O
O
Ruuskanen
O V
OV
Renkonen
E
E
Herva
D000293:Adolescent; D000380:Agranulocytosis / Q000188:drug therapy*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000401:mortality; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003023:Cloxacillin / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005334:Fever / Q000188:drug therapy*; D005387:Finland; D005436:Floxacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D009503:Neutropenia / Q000188:drug therapy* / Q000401:mortality; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors
D005436:Floxacillin; D002442:Ceftazidime; D003023:Cloxacillin; D010878:Piperacillin